EP300 and acute myeloid leukemia: Consistent with prior studies, A-485 treatment reduced H3K27Ac level in both MLL-r and MLL wild-type AML cells (Fig. 5A Additional file 1: Fig. S6A), mirroring the observation of EP300 or CREBBP deletion (Fig. 5B, Additional file 1: Fig. S6B).